Mariner
FATE icon

Mariner’s Fate Therapeutics FATE Stock Holding History

Mariner’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$118K Buy
98,295
+83,406
+560% +$102K ﹤0.01% 3292
2025
Q4 		$14.6K Sell
14,889
-8,041
-35% -$9.66K ﹤0.01% 3503
2025
Q3 		$28.9K Buy
22,930
+11,393
+99% +$12.3K ﹤0.01% 3491
2025
Q2 		$12.9K Buy
+11,537
New +$13.4K ﹤0.01% 3446

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mariner's FATE Position: Q1 2026 in Review

Mariner increased its Fate Therapeutics (FATE) stake by 560% in Q1 2026, buying an estimated $102K and bringing the position to 98,295 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #3292.

Mariner first reported a position in FATE in Q2 2025 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Mariner held 98,295 shares of Fate Therapeutics worth $118K as of Q1 2026.
  • Mariner bought 83,406 Fate Therapeutics shares in Q1 2026, an estimated $102K.
  • Fate Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #3292 holding.
  • Mariner first reported a position in Fate Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.